←
Mark Skinner161 posts
Mark Skinner avatar

Mark Skinner

@MSkinnerDC
◷ Joined September 2013▧ 29 Photos and videos
World Federation of Hemophilia avatar
⟳ Mark Skinner retweeted
World Federation of Hemophilia@wfhemophilia·6 Sep 2025

The global #BleedingDisorders community is celebrating a milestone achievement! The #WHO has approved the WFH proposals to update the Essential Medicines List and the Essential Medicines List for Children. Stay tuned for more news on the work carried out by the WFH.

Post attachment
Radoslaw Kaczmarek avatar
⟳ Mark Skinner retweeted
Radoslaw Kaczmarek@RKaczmarekDr·12 Aug 2025

Thank you for having me @VJHemOnc Several colleagues and I also published a reflective article on this: tinyurl.com/Why-is-the-uptak… I summarized some key points in the video. SPOILER ALERT It is not due to lack of interest in gene therapy. #hemophilia

Post attachment
VJHemOnc@VJHemOnc7 Aug 2025

Why has the uptake of gene therapy in #hemophilia been less than expected? Is there limited interest in these therapies? 🤔🩸🧬 We caught up with @RKaczmarekDr of @IUMedSchool to get the answers to these questions: 👉 ow.ly/LFKL50WAwFA 👈 #GeneTherapy #Hematology #ISTH2025

Mark Skinner avatar
Mark Skinner@MSkinnerDC·18 Jul 2025

Why is the uptake of gene therapy in hemophilia less than expected? rpthjournal.org/article/S247… Please review our current article detailing the complex decision making process, one that goes well beyond "patient interest". The desire to be cured remains strong.

Post attachmentPost attachment
Mark Skinner avatar
Mark Skinner@MSkinnerDC·10 Jul 2025

We’re deeply saddened by the passing of Drs. Pattraporn Isarangkura & Carol Kasper—true giants in our community. Appropriately jointly named as the 1st recipients of the @wfhemophilia Volunteer Award (2004). We honor their legacy with deep gratitude—their impact will live on.

Post attachment
Brian O Mahony avatar
⟳ Mark Skinner retweeted
Brian O Mahony@Brianhemophilia·6 Dec 2024

Conclusions: Methodological approach used resulted in categorisation of evidence as weak. Failure to recognise the advantages of modern therapies. May misguide treaters, payers and Governments as they overlook important evidence and incorporate obsolete treatment principles 2/3

Post attachment
Brian O Mahony avatar
⟳ Mark Skinner retweeted
Brian O Mahony@Brianhemophilia·6 Dec 2024

A critique of the ISTH Haemophilia Guidelines was published in #Haemophilia Journal today with 49 eminent authors representing a global mixture of expertise, all united in their serious concerns about these guidelines which were already outdated on publication 1/3

Post attachment
Mark Skinner avatar
Mark Skinner@MSkinnerDC·9 Dec 2024

The methodology should have allowed data from registries and real-world studies, integrated multiple patient-related outcomes and expert opinion. The strict application led ISTH to limited, conservative, and unambitious guidelines failing to consider newer treatments.

Mark Skinner avatar
Mark Skinner@MSkinnerDC·9 Dec 2024

The puristic approach of the ISTH Guideline development, without consideration of accepted adaptations to GRADE implementation, led to recommendations that have been widely deemed invalid and obsolete by expert healthcare professionals and those living with hemophilia.

Post attachment
Mark Skinner avatar
Mark Skinner@MSkinnerDC·9 Dec 2024

Contrasting Approaches in the Implementation of GRADE Methodology in Guidelines for Haemophilia and VWD. onlinelibrary.wiley.com/doi/… This article developed by a global team of 48 experts and international organizations rigorously examines a number of GRADE methodology adaptations.

Brian O Mahony avatar
⟳ Mark Skinner retweeted
Brian O Mahony@Brianhemophilia·26 Jun 2023

In the paper, we review the data leading to the regulatory authorization in Europe of valoctocogene roxaparvovec, an adeno-associated virus (AAV)-5 gene therapy to treat haemophilia A and etranacogene dezaparvovec in the United States and Europe to treat haemophilia B. 2/3

Brian O Mahony avatar
⟳ Mark Skinner retweeted
Brian O Mahony@Brianhemophilia·26 Jun 2023

Paper just published online. The decision to take a gene therapy product is one in which an informed, holistic and shared decision-making approach must be employed. Bias on the part of healthcare professionals and people with haemophilia must be addressed and minimized. 1/3

Post attachment